Patents Assigned to Creagene, Inc.
  • Use of MLN51 gene and protein
    Patent number: 8513028
    Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: August 20, 2013
    Assignee: Creagene Inc.
    Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
  • Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP)
    Patent number: 7138274
    Abstract: The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide sequence encoding an additional polioviral cleavage site; and (c) a nucleotide sequence of a conformational epitope encoding a VP1 neutralizing epitope of poliovirus type 2 or 3 and linked to the nucleotide sequence of (b).
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: November 21, 2006
    Assignee: Creagene, Inc.
    Inventors: Yong-Soo Bae, Sang-Gu Lee, Hye-Rhan Jeong, Dong-Sung Lee, Ki-Tae Kim, Dae-You Kim
  • Cytoplasmic transduction peptides and uses thereof
    Patent number: 7101844
    Abstract: The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: September 5, 2006
    Assignee: Creagene, Inc.
    Inventors: Dae-You Kim, Hae-Keun Oh, Chang-Hyun Kim, Jung-Hwan Kim, Choon-Ju Jeon, Ki-Tae Kim, Yong-Soo Bae, In-Soo Choi
  • Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus
    Patent number: 6780618
    Abstract: The present invention relates to (a) methods for improving a genetic stability of an insert nucleotide sequence in a recombinant single-stranded RNA virus vector, which comprises performing a mutagenesis of the foreign insert nucleotide sequence to provide even distribution of G/C content throughout the overall foreign insert nucleotide sequence and/or to increase G/C content of the foreign insert without substantially causing amino acids substitutions (b) a recombinant single-stranded RNA virus comprising an insert nucleotide sequence with improved genetic stability and (c) a recombinant poliovirus comprising an insert nucleotide sequence with improved genetic stability.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 24, 2004
    Assignee: CreaGene Inc.
    Inventors: Sang-Gu Lee, Dae-You Kim, Ki-Tae Kim, Yong-Soo Bae
  • Replication-competent recombinant Sabin type 1 strain of poliovirus
    Patent number: 6696289
    Abstract: A replication-competent recombinant Sabin type 1 poliovirus vector containing a sequence coding for multiple cloning site and 3C-protease cleavage site is provided. This vector makes it easy to introduce various vaccine genes from infectious viruses to the Sabin 1 poliovirus, and facilitates to produce chimeric Sabin 1 polioviruses that are expected to be powerful oral mucosal vaccines against several infectious viral diseases.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: February 24, 2004
    Assignee: Creagene Inc.
    Inventors: Yong Soo Bae, Hye Rhan Jung